with PCG, supporting loss of function as a mechanism of CYP1B1 variants causing PCG (Libby et al., 2003) . Over 200 pathogenic sequence variants have been reported in CYP1B1 (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CYP1B1), however deletions of the gene have seldom been reported (Damjanovich, Baldwin, Lewis, & Bayrak-Toydemir, 2013; Kelberman et al., 2011; Milla et al., 2013; Stoilov, et al., 1997) . In this study, we report an individual with PCG and a homozygous CYP1B1 deletion arising from paternal uniparental isodisomy of chromosome 2.
| CASE REPORT
The study was conducted in accordance with the revised Declaration of Helsinki and participants were recruited with the approval of the Southern Adelaide Clinical Human Research Ethics Committee. The proband and his family members were enrolled as part of The Australian and New Zealand Registry of Advanced Glaucoma and gave their informed consent (Souzeau et al., 2012) . The proband was a 15-year-old boy and the second child of nonconsanguineous Indian parents. He presented with bilateral significant corneal clouding, enlarged cornea 12 mm horizontally and raised IOP at birth. Right trabeculectomies were performed at 4 weeks and 3 months of age, however this eye became densely amblyopic. His better left eye had a trabeculectomy with Mitomycin C antimetabolite at age 32 months. Sequential left then right Ahmed tube surgery took place at age 4 and 5 years. These surgeries all took place in India. His family moved to Australia when he was 11 years. At that time his right eye was blind with perception of light, he had IOP of 30 mmHg, band keratopathy, a small pupil and dense cataract limiting the view of his optic nerve ( Figure  1 ). The better left eye has nystagmus, vision of 3/15, IOP in the mid-teens on maximal topical medical therapy and since age 13 also acetazolamide 250 mg bd. His most recent field test had generalized reduced sensitivity, with a left nasal step. Both parents and his older sister were examined and were unaffected.
| GENETIC ANALYSIS
Genomic DNA was extracted from venous blood of the proband, his parents, and his sister. CYP1B1 sequencing was performed on the proband's DNA through the NATA (National Association of Testing Authorities) accredited laboratories of SA Pathology at Flinders Medical Centre (Adelaide, Australia) as previously described (Souzeau, Hayes, Zhou, et al., 2015) . Amplification of the two coding exons of CYP1B1 failed, suggesting a potential gene deletion (data not shown).
CYP1B1 was then analyzed for copy number variation by Multiplex Ligation-dependent Probe Amplification (MLPA) using the SALSA P128 Cytochrome P450 probemix (MRC Holland, Amsterdam, The Netherlands) according to the manufacturers' protocol. MLPA analysis of CYP1B1 indicated an abnormal copy number in the proband's DNA, characteristic of a homozygous deletion of the entire gene. MLPA analysis of both parents was then performed, and revealed in the father the loss of a single allele of CYP1B1 but indicated a normal copy number for all exons of CYP1B1 in the mother (Figure 2) .
To investigate the extent of the CYP1B1 gene deletion in the proband and the possibility of uniparental disomy (UPD), a SNP array (Illumina Infinium CytoSNP-850K BeadChip) was conducted. Array result of the proband revealed an interstitial homozygous deletion of 119kb on chromosome 2q22.2 (chr2: 38 239 356-38 358 664, GRCh37/hg19 assembly) encompassing the entire CYP1B1 gene as well as the RMDN2 gene (MIM 611872). The RMDN2 gene has not been associated with any clinical phenotype. Paternal isodisomy for the entire chromosome 2 was identified, confirming that the homozygous CYP1B1 deletion in the child originated from 
| DISCUSSION
UPD is a rare event that arises when an individual with a diploid genome carries both homologs of a pair of chromosomes from one parent (uniparental heterodisomy) or both copies of a single parental chromosome (uniparental isodisomy) (Engel, 1980) . UPD can result in clinically recognizable phenotypes through imprinting defects, mosaicism, or unmasking of homozygosity for pathogenic variants inherited from one parent in autosomal recessive genes. Paternal UPD2 is relatively rare and has generally been reported following genetic analysis of individuals homozygous for variants in autosomal recessive genes consistent with their phenotype (Baskin, Geraghty, & Ray, 2010; Chavez, Valdez, & Vilchis, 2000; Lopez-Garrido, Campos-Mollo, Harto, & Escribano, 2009; Shen et al., 2018; Thompson et al., 2002) . One of these cases involved a homozygous CYP1B1 missense variant due to paternal UPD2 in a patient with PCG (Lopez-Garrido et al., 2009 ). We previously showed that deletion of the entire CYP1B1 gene is not a major contributor to PCG (Souzeau, Hayes, Ruddle, et al., 2015) . CYP1B1 deletions have only been reported three times, with deletion sizes ranging from 146kb to 193kb (Figure 3) (Damjanovich et al., 2013; Kelberman et al., 2011; Milla et al., 2013) . The deletion reported in this study is the smallest deletion encompassing the entire CYP1B1 gene, with a size of 119kb. All reported deletions included part of the RMDN2 gene that has not been associated with any clinical phenotype.
The confirmation of UPD as the cause of variant homozygosity has important implications for the family in terms of genetic counseling. The parents can be counseled that the risk of recurrence for other children is low, as opposed to the 25% risk of recurrence usually reported for variants in autosomal recessive genes such as CYP1B1. Similarly, the occurrence of phenotypically normal individuals with paternal UPD2 does not support a significant role for paternally imprinted genes on chromosome 2 (Keller et al., 2009; Ou et al., 2013) . This is supported by the absence of additional clinical features in the proband reported in this study.
In summary, this is the first report of a homozygous CYP1B1 whole gene deletion due to paternal UPD2 and associated with PCG. This study illustrates the importance of genetic testing in identifying the underlying molecular cause of the disease and in providing adequate genetic counseling regarding the possible recurrence risks.
